Genome‐Wide DNA Methylation Study Identifies Significant Epigenomic Changes in Osteoarthritic Cartilage

  • Matlock A. Jeffries
    University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation Oklahoma City
  • Madison Donica
    Oklahoma Medical Research Foundation Oklahoma City
  • Lyle W. Baker
    University of Oklahoma Oklahoma City
  • Michael E. Stevenson
    University of Oklahoma Health Sciences Center Oklahoma City
  • Anand C. Annan
    University of Oklahoma Health Sciences Center Oklahoma City
  • Mary Beth Humphrey
    University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, and Department of Veterans Affairs Medical Center Oklahoma City Oklahoma
  • Judith A. James
    University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation Oklahoma City
  • Amr H. Sawalha
    Oklahoma Medical Research Foundation, Oklahoma City, and University of Michigan Ann Arbor

抄録

<jats:sec><jats:title>Objective</jats:title><jats:p>To perform a genome‐wide DNA methylation study to identify DNA methylation changes in osteoarthritic (OA) cartilage tissue.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The contribution of differentially methylated genes to OA pathogenesis was assessed by bioinformatic analysis, gene expression analysis, and histopathologic severity correlation. Genome‐wide DNA methylation profiling of >485,000 methylation sites was performed on eroded and intact cartilage from within the same joint of 24 patients undergoing hip arthroplasty for OA. Genes with differentially methylated CpG sites were analyzed to identify overrepresented gene ontologies, pathways, and upstream regulators. The messenger RNA expression of a subset of differentially methylated genes was analyzed by reverse transcription–polymerase chain reaction. Histopathology was graded by modified Mankin score and correlated with DNA methylation.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We identified 550 differentially methylated sites in OA. Most (69%) were hypomethylated and enriched among gene enhancers. We found differential methylation in genes with prior links to OA, including <jats:italic>RUNX1</jats:italic>, <jats:italic>RUNX2</jats:italic>, <jats:italic>DLX5</jats:italic>, <jats:italic>FURIN</jats:italic>, <jats:italic>HTRA1</jats:italic>, <jats:italic>FGFR2</jats:italic>, <jats:italic>NFATC1</jats:italic>, <jats:italic>SNCAIP</jats:italic>, and <jats:italic>COL11A2</jats:italic>. Among these, <jats:italic>RUNX1</jats:italic>, <jats:italic>HTRA1</jats:italic>, <jats:italic>FGFR2</jats:italic>, and <jats:italic>COL11A2</jats:italic> were also differentially expressed. Furthermore, we found differential methylation in approximately one‐third of known OA susceptibility genes. Among differentially methylated genes, upstream regulator analysis showed enrichment of <jats:italic>TGFB1</jats:italic> (<jats:italic>P</jats:italic> = 4.40 × 10<jats:sup>−5</jats:sup>) and several microRNAs including miR‐128 (<jats:italic>P</jats:italic> = 4.48 × 10<jats:sup>−13</jats:sup>), miR‐27a (<jats:italic>P</jats:italic> = 4.15 × 10<jats:sup>−12</jats:sup>), and miR‐9 (<jats:italic>P</jats:italic> = 9.20 × 10<jats:sup>−10</jats:sup>). Finally, we identified strong correlations between 20 CpG sites and the histologic Mankin score in OA.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Our data implicate epigenetic dysregulation of a host of genes and pathways in OA, including a number of OA susceptibility genes. Furthermore, we identified correlations between CpG methylation and histologic severity in OA.</jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

問題の指摘

ページトップへ